All of the parties who participated in last week's Supreme Court oral arguments about the patentability of human genes - the justices, the Department of Justice, Myriad Genetics Inc., and the American Civil Liberties Union - seem to be looking for ways to limit the fallout from the case to prevent it from inflicting broad damage to biotech innovation.

Regardless of how the court rules in the case, it may take a long time to assess the consequences, intended and especially unintended, on the IP landscape.